摘要
目的探讨奥曲肽联合前列地尔治疗肝肾综合征的疗效及安全性。方法将72例肝肾综合征患者按照入院顺序分为观察组36例和对照组36例,两组给予常规治疗,对照组在此基础上加用前列地尔;治疗组在对照组基础上加用奥曲肽。两组均治疗14d,评估临床疗效及不良反应。结果治疗组总有效率明显高于对照组,两组有效率比较具有统计学意义(χ2=4.30,P<0.05)。所有患者不良反应均可耐受,且未见严重不良反应发生。结论奥曲肽联合前列地尔治疗肝肾综合征能够明显改善患者的肾功能,降低门静脉压力,且具有良好安全性。
Objective To observe therapeutic efficacy and safety of octreotide combined with alprostadil in the treatment of hepatorenal Syndrome. Methods Using the digital table method,72 patients diagnosed with hepatorenal Syndrome by clinic,were randomized into observation group（ n = 36） and control group（ n = 36）. Both groups were given routine therapy. On the basis of routine therapy,control group was given Intravenous injectioning of alprostadil; observation group was given octreotide on the basis of control group. Treatment course of 2 groups lasted for 14 days. The clinical and incidence of adverse reaction were analyzed. Results Total effective rate of observation group was significantly higher than that of control group,there was statistical significance（ χ^2= 4. 30,P〈0. 05）. ADR of all patients were tolerable,and no severe ADR was found. Conclusion Octreotide combined with alprostadil is an effective method of hepatorenal Syndrome,can improve the renal function and reduce portal pressure with significant clinical effect,and it＇s safety.
出处
《医药论坛杂志》
2015年第8期9-11,共3页
Journal of Medical Forum
关键词
肝肾综合征
奥曲肽
前列地尔
肾小球滤过率
Hepatorenal Syndrome
Octreotide
Alprostadil
Glomerular filtration rate
